Apontis Pharma AG

XTRA:APPH Voorraadrapport

Marktkapitalisatie: €81.0m

Apontis Pharma Beheer

Beheer criteriumcontroles 1/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Bruno Wohlschlegel

Algemeen directeur

€181.0k

Totale compensatie

Percentage CEO-salaris59.7%
Dienstverband CEO1.2yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuur2.5yrs

Recente managementupdates

Recent updates

We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Oct 17
We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Further Upside For Apontis Pharma AG (ETR:APPH) Shares Could Introduce Price Risks After 35% Bounce

Oct 17
Further Upside For Apontis Pharma AG (ETR:APPH) Shares Could Introduce Price Risks After 35% Bounce

Health Check: How Prudently Does Apontis Pharma (ETR:APPH) Use Debt?

Jun 18
Health Check: How Prudently Does Apontis Pharma (ETR:APPH) Use Debt?

Potential Upside For Apontis Pharma AG (ETR:APPH) Not Without Risk

Apr 05
Potential Upside For Apontis Pharma AG (ETR:APPH) Not Without Risk

We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Dec 02
We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth

Not Many Are Piling Into Apontis Pharma AG (ETR:APPH) Stock Yet As It Plummets 27%

Jul 29
Not Many Are Piling Into Apontis Pharma AG (ETR:APPH) Stock Yet As It Plummets 27%

Apontis Pharma's (ETR:APPH) Robust Earnings Are Supported By Other Strong Factors

Apr 08
Apontis Pharma's (ETR:APPH) Robust Earnings Are Supported By Other Strong Factors

Analyse CEO-vergoeding

Hoe is Bruno Wohlschlegel's beloning veranderd ten opzichte van Apontis Pharma's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-€7m

Mar 31 2024n/an/a

-€9m

Dec 31 2023€181k€108k

-€11m

Compensatie versus markt: Bruno's total compensation ($USD196.10K) is below average for companies of similar size in the German market ($USD488.36K).

Compensatie versus inkomsten: Insufficient data to compare Bruno's compensation with company performance.

CEO

Bruno Wohlschlegel (56 yo)

1.2yrs

Tenure

€180,964

Compensatie

Mr. Bruno Wohlschlegel serves as Member of Management Board at Apontis Pharma AG since September 01, 2023 and served as its Chief Executive Officer since September 01, 2023. He is Chairman of Management Bo...

Bestuursleden

NaamPositieTenureCompensatieEigendom
Edin Hadzic
Member of Supervisory Boardno datageen gegevensgeen gegevens
Olaf Elbracht
Independent Deputy Chairman of Supervisory Board2.5yrsgeen gegevensgeen gegevens
Matthias Wiedenfels
Independent Chairman of Supervisory Board2.5yrsgeen gegevensgeen gegevens
Christian Bettinger
Member of Supervisory Boardno datageen gegevensgeen gegevens
Anna Picciolo-Lehrke
Independent Member of Supervisory Board2.5yrsgeen gegevensgeen gegevens

2.5yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: APPH's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.